Stock Events

Stock Events

AIM ImmunoTech 

$0.54
43
-$0.01-1.82% Today

Statistics

Day High
0.6
Day Low
0.55
52W High
2.88
52W Low
0.09
Volume
279,389
Avg. Volume
4,621,623
Mkt Cap
0
P/E Ratio
-
Dividend Yield
48.67%
Dividend
0.26

Upcoming

15
MAY
Dividend Ex
Estimated
 
17
MAY 27
Dividend Ex
Estimated
 
15
MAY 28
Dividend Ex
Estimated
 

Dividends

48.67%Dividend Yield
May 25
$0.27
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

14MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
Next
-8
-5.35
-2.71
-0.06
Expected EPS
-1.078921
Actual EPS
N/A

Financials

-10,188.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
340,000Revenue
-34.64MNet Income

Analyst Ratings

$22.00Average Price Target
The highest estimate is 22.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AIM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation operates in the biopharmaceutical field focusing on the discovery, development, and commercialization of proprietary therapeutics, including those that affect the immune system's function, which competes with AIM's immunotherapy approaches.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that modulate the immune system, directly competing with AIM's product pipeline.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. focuses on mRNA-based therapies, some of which are designed to activate the immune system against cancer and infectious diseases, competing with AIM's immunotherapeutic strategies.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE operates in the field of mRNA technology and immunotherapy, developing treatments that stimulate the body's immune response, similar to AIM's focus, making them direct competitors in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. is involved in the development of vaccines that stimulate the immune system, competing with AIM ImmunoTech's efforts in immune system modulation for disease prevention and treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including the development of immune-modulating drugs, which places it in direct competition with AIM in the field of immunotherapies.
Cytodyn
CYDY
Mkt Cap302.34M
CytoDyn Inc. focuses on the development and commercialization of novel therapeutics for the treatment of immune, viral, and other serious diseases, competing with AIM's focus on immune-based therapies.
iBio
IBIO
Mkt Cap32.41M
iBio, Inc. is a biotechnology company that focuses on developing plant-based biopharmaceuticals, including vaccines and therapeutic proteins that modulate the immune system, making it a competitor to AIM in the broader field of immune-based therapies.

About

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company?s primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
Mr. Thomas K. Equels Esq., J.D., M.S.
Employees
21
Country
US
ISIN
US00901B3033

Listings

LSE
GB
0A4Y.LSE
F
DE
HXB.F
OTCM
US
AIMI
BOATS
BOATS
AIM.BOATS

0 Comments

Share your thoughts

FAQ

What is AIM ImmunoTech stock price today?▼
The current price of AIM is $0.54 USD — it has decreased by -1.82% in the past 24 hours. Watch AIM ImmunoTech stock price performance more closely on the chart.
What is AIM ImmunoTech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AIM ImmunoTech stocks are traded under the ticker AIM.
Is AIM ImmunoTech stock price growing?▼
AIM stock has fallen by -21.33% compared to the previous week, the month change is a -29.58% fall, over the last year AIM ImmunoTech has showed a +350.04% increase.
When is the next AIM ImmunoTech earnings date?▼
AIM ImmunoTech is going to release the next earnings report on May 14, 2026.
What is AIM ImmunoTech revenue for the last year?▼
AIM ImmunoTech revenue for the last year amounts to 340,000 USD.
What is AIM ImmunoTech net income for the last year?▼
AIM net income for the last year is -34.64M USD.
Does AIM ImmunoTech pay dividends?▼
Yes, AIM dividends are paid semi-annual. The last dividend per share was 0.27 USD. As of today, Dividend Yield (FWD)% is 48.67%.
How many employees does AIM ImmunoTech have?▼
As of April 02, 2026, the company has 21 employees.
In which sector is AIM ImmunoTech located?▼
AIM ImmunoTech operates in the Health Care sector.
When did AIM ImmunoTech complete a stock split?▼
The last stock split for AIM ImmunoTech was on January 09, 2026 with a ratio of 1001:1000.
Where is AIM ImmunoTech headquartered?▼
AIM ImmunoTech is headquartered in Ocala, US.